DAPSONE PYRIMETHAMINE COMPARED WITH AEROSOLIZED PENTAMIDINE AS PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA AND TOXOPLASMOSIS IN HIV-INFECTION

被引:199
作者
GIRARD, PM
LANDMAN, R
GAUDEBOUT, C
OLIVARES, R
SAIMOT, AG
JELAZKO, P
GAUDEBOUT, C
CERTAIN, A
BOUE, F
BOUVET, E
LECOMPTE, T
COULAUD, JP
机构
[1] HOP BICHAT CLAUDE BERNARD,SERV MALAD INFECT & TROP,PARIS,FRANCE
[2] HOP BICHAT CLAUDE BERNARD,THE PHARM,PARIS,FRANCE
[3] HOP ST LOUIS,SERV MALAD INFECT & TROP,F-75010 PARIS,FRANCE
[4] SERV MED INTERNE,CLAMART,FRANCE
关键词
D O I
10.1056/NEJM199305273282102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Pneumocystis carinii pneumonia and toxoplasmic encephalitis are frequent life-threatening opportunistic infections in patients with human immunodeficiency virus (HIV) infection. Primary prophylaxis against P. carinii pneumonia is now common, but there are few data on regimens for primary prophylaxis against toxoplasmosis. Methods. We conducted a randomized trial that compared two prophylactic regimens: dapsone (50 mg per day) plus pyrimethamine (50 mg per week) was compared with aerosolized pentamidine (300 mg per month). The patients had symptomatic HIV infection, no history of P. carinii pneumonia or symptomatic toxoplasmosis, and CD4+ counts below 200 per cubic millimeter (0.2 x 10(9) per liter). Results. In an intention-to-treat analysis, after a median follow-up of 539 days P. carinii pneumonia developed in 10 patients in each group, whereas toxoplasmosis developed in 32 of 176 patients in the pentamidine group and 19 of 173 patients in the dapsone-pyrimethamine group. Those assigned to pentamidine had a risk of P. carinii pneumonia that was similar to the risk in those assigned to dapsone-pyrimethamine (adjusted relative risk, 1.13; 95 percent confidence interval, 0.44 to 2.92; P = 0.79), but a higher risk of toxoplasmosis (adjusted relative risk, 1.81; 95 percent confidence interval, 1.12 to 2.94; P = 0.02). Among the 262 patients with serologic evidence of past exposure to Toxoplasma gondii, the relative risk of symptomatic toxoplasmosis was 2.37 times higher in those assigned to pentamidine (95 percent confidence interval, 1.3 to 4.4; P = 0.006). More patients discontinued dapsone-pyrimethamine than pentamidine because of toxicity (42 vs. 3; P<0.001). Survival was similar in the two groups. Conclusions. For primary prevention of P. carinii pneumonia, dapsone-pyrimethamine is as effective, though not as well tolerated, as aerosolized pentamidine. Dapsone-pyrimethamine also prevents first episodes of toxoplasmosis.
引用
收藏
页码:1514 / 1520
页数:7
相关论文
共 54 条
[11]  
COX DR, 1972, J R STAT SOC B, V34, P187
[12]   TREATMENT OF TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS - A RANDOMIZED TRIAL COMPARING PYRIMETHAMINE PLUS CLINDAMYCIN TO PYRIMETHAMINE PLUS SULFADIAZINE [J].
DANNEMANN, B ;
MCCUTCHAN, JA ;
ISRAELSKI, D ;
ANTONISKIS, D ;
LEPORT, C ;
LUFT, B ;
NUSSBAUM, J ;
CLUMECK, N ;
MORLAT, P ;
CHIU, J ;
VILDE, JL ;
ORELLANA, M ;
FEIGAL, D ;
BARTOK, A ;
HESELTINE, P ;
LEEDOM, J ;
REMINGTON, J .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :33-43
[13]   ANTITOXOPLASMA EFFECTS OF DAPSONE ALONE AND COMBINED WITH PYRIMETHAMINE [J].
DEROUIN, F ;
PIKETTY, C ;
CHASTANG, C ;
CHAU, F ;
ROUVEIX, B ;
POCIDALO, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (02) :252-255
[14]  
DEROUIN F, 1986, BIOMED PHARMACOTHER, V40, P231
[15]   SAFETY AND EFFICACY OF SULFAMETHOXAZOLE AND TRIMETHOPRIM CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN AIDS [J].
FISCHL, MA ;
DICKINSON, GM ;
LAVOIE, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (08) :1185-1189
[16]  
GIRARD PM, 1989, LANCET, V1, P1348
[17]   TOXOPLASMA-GONDII SEROLOGY IN HIV-INFECTED PATIENTS - THE DEVELOPMENT OF CENTRAL-NERVOUS-SYSTEM TOXOPLASMOSIS IN AIDS [J].
GRANT, IH ;
GOLD, JWM ;
ROSENBLUM, M ;
NIEDZWIECKI, D ;
ARMSTRONG, D .
AIDS, 1990, 4 (06) :519-521
[18]   A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021 [J].
HARDY, WD ;
FEINBERG, J ;
FINKELSTEIN, DM ;
POWER, ME ;
HE, W ;
KACZKA, C ;
FRAME, PT ;
HOLMES, M ;
WASKIN, H ;
FASS, RJ ;
POWDERLY, WG ;
STEIGBIGEL, RT ;
ZUGER, A ;
HOLZMAN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) :1842-1848
[19]   TREATMENT FOR CEREBRAL TOXOPLASMOSIS PROTECTS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS [J].
HEALD, A ;
FLEPP, M ;
CHAVE, JP ;
MALINVERNI, R ;
RUTTIMANN, S ;
GABRIEL, V ;
RENOLD, C ;
SUGAR, A ;
HIRSCHEL, B .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (10) :760-763
[20]   A CONTROLLED-STUDY OF INHALED PENTAMIDINE FOR PRIMARY PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA [J].
HIRSCHEL, B ;
LAZZARIN, A ;
CHOPARD, P ;
OPRAVIL, M ;
FURRER, HJ ;
RUTTIMANN, S ;
VERNAZZA, P ;
CHAVE, JP ;
ANCARANI, F ;
GABRIEL, V ;
HEALD, A ;
KING, R ;
MALINVERNI, R ;
MARTIN, JL ;
MERMILLOD, B ;
NICOD, L ;
SIMONI, L ;
VIVIRITO, MC ;
ZERBONI, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) :1079-1083